Clinically, two predominant subtypes emerge based on receptor status: the ER-positive, PR-positive, HER-2 amplification type, and the Triple-Negative Breast Cancer (TNBC) (Xu et al., 2022). Here, PGR is linked to triple-negative breast carcinoma.